ProCE Banner Activity

Updated AAD Guidance on Systemic Treatment for Atopic Dermatitis

Clinical Thought

More than half of people with moderate to severe atopic dermatitis (AD) report inadequate control of their symptoms. In this commentary, an expert discusses the 2024 updates to the American Academy of Dermatology systemic therapy guidelines for AD, the first since 2014 for this condition.

Released: July 18, 2024

Expiration: July 17, 2025

Share

Faculty

Benjamin Ungar

Benjamin Ungar, MD

Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Assistant Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals

Sanofi

Disclosure

Primary Author

Benjamin Ungar, MD

Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Assistant Professor, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Benjamin Ungar, MD: consultant/advisor: Arcutis Biotherapeutics, Bristol Myers Squibb, Castle Biosciences, Fresenius Kabi, Galderma, Janssen, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, UCB; researcher (paid to institution): Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, Sanofi.